Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis B

Area of Science:

• Immunology
• Hepatology
• Pulmonology

Background:

• Sarcoidosis is a rare complication of interferon-alpha (IFN-alpha) therapy.
• Previous reports link sarcoidosis to IFN-alpha treatment for malignant diseases, essential thrombocytosis, and chronic hepatitis C.
• The occurrence of sarcoidosis in chronic hepatitis B patients treated with IFN-alpha has not been previously described.

Purpose of the Study:

• To report the first case of sarcoidosis in a patient with chronic hepatitis B treated with IFN-alpha.
• To investigate the potential role of IFN-alpha in triggering sarcoidosis.

Main Methods:

• A 64-year-old male with chronic hepatitis B received recombinant IFN-alpha-2b for 28 weeks.
• Diagnostic imaging (chest X-ray, HRCT) revealed mediastinal lymphadenopathy.
• Thoracoscopy with lymph node biopsy confirmed sarcoidosis histologically.

Main Results:

• The patient developed bilateral hilar masses and mediastinal lymphadenopathy 12 months post-IFN-alpha therapy.
• Histological diagnosis confirmed sarcoidosis.
• Complete normalization of lymphadenopathy occurred within 1 year without specific treatment.

Conclusions:

• Interferon-alpha may trigger sarcoidosis in susceptible individuals, potentially by stimulating T-helper 1 (Th1) immune responses.
• This case highlights the importance of monitoring for sarcoidosis in patients undergoing IFN-alpha therapy, particularly those with chronic hepatitis B.
• The findings suggest a possible mechanism involving IFN-alpha-induced Th1 immune responses in the pathogenesis of sarcoidosis.